New study published in JAMA Oncology!
Our recent article shows that brain-targeting autoantibodies found in lung cancer patients may be responsible for cancer-related cognitive impairment.
In this prospective, cross-sectional study we included 167 patients with lung cancer. Brain-directed autoantibodies were found in 36.5% of all patients: 19.8% had known neuronal autoantibodies and 16.8% had autoantibodies against currently unknown antigens that were detected by immunohistochemistry. Cognitive impairment was found in as much as 67.0% of patients. Importantly, patients with neuronal autoantibodies had increased odds of cognitive impairment compared with patients without autoantibodies. Interestingly, autoantibodies against currently unknown neuronal antigens were also associated with higher odds of cognitive impairment.
Therefore, our study suggests that neuronal autoantibodies might represent a pathogenic factor in cancer-related cognitive impairment among patients with lung cancer.
There is a JAMA Oncology podcast interview with Frederik and Carsten at: https://edhub.ama-assn.org/jn-learning/audio-player/18621621 and an editorial about our study at: https://jamanetwork.com/journals/jamaoncology/article-abstract/2781393